Potency estimation of recombinant factor VIII: effect of assay method and standard.
Large potency discrepancies between the chromogenic and one-stage clotting methods have been reported for patients' plasma samples following the infusion of recombinant factor VIII (rFVIII) concentrates. We have investigated the potency estimation of two different full-length rFVIII concentrates using both assay methods relative to both plasma and concentrate standards. Potencies by the chromogenic method were significantly higher (53% and 45%) than potencies by the one-stage clotting method when a plasma standard was used. In contrast, there was no significant potency difference between methods when a concentrate standard was used. Time-course studies into thrombin and activated factor X (FXa) generation, in modified clotting and chromogenic methods, respectively, revealed that the two rFVIII concentrates behaved very similarly to the concentrate standard, whereas the plasma standard showed slightly more rapid thrombin generation and markedly slower FXa generation. The different behaviour of rFVIII and plasma FVIII in the chromogenic method is proposed as the main cause of the methods-based potency discrepancy. The results support the use of a concentrate standard to measure rFVIII in post-infusion plasma.
Hubbard
A R
AR
Division of Haematology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK. thubbard@nibsc.ac.uk
Bevan
S A
SA
Weller
L J
LJ
D001780:Blood Coagulation Tests / Q000379:methods*; D005169:Factor VIII / Q000008:administration & dosage* / Q000592:standards; D015951:Factor Xa / Q000378:metabolism; D006467:Hemophilia A / Q000097:blood* / Q000628:therapy; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000592:standards; D012015:Reference Standards; D013917:Thrombin / Q000378:metabolism; D013997:Time Factors
D011994:Recombinant Proteins; D005169:Factor VIII; D013917:Thrombin; D015951:Factor Xa